Posted by Michael Wonder on 27 Dec 2020
Pandemic delays FDA decision on Biocon's bevacizumab application
27 December 2020 - For Bengaluru, Karnataka, India–based Biocon Biologics, the pandemic has interrupted the FDA review process for its planned bevacizumab biosimilar.
Biocon has been informed by the FDA that a decision on its biologics license application for the bevacizumab biosimilar candidate MYL-14020, referencing Avastin, has been deferred while the agency awaits an opportunity to inspect the company’s manufacturing facility.
